Article
Montelukast as a novel therapeutic approach in metastatic uveal melanoma harboring a CYSLTR2 mutation: a translational case report.
ESMO open - 1 Jan 2026
Smarsly D, Kreuzberg N, Langhorst C, Scheffler M, Siebolts U, Lennartz S, Koll P, Glaser A-C, Franklin C
Abstract excerpt
BACKGROUND: Uveal melanoma (UM), the most common primary intraocular malignancy in adults, has limited systemic treatment options in the metastatic setting. Recent insights into cysteinyl leukotriene receptors (CysLTRs)-particularly CYSLTR2 mutations (prevalence 2%-4%)-suggest new therapeutic approaches for patients who progress despite standard therapies. CASE: We report the case of a 59-year-old male with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.